



RESEARCH ARTICLE

“EFFECTS OF LEVOTHYROXINE REPLACEMENT THERAPY ON INSULIN SENSITIVITY IN SUBJECTS WITH OVERT HYPOTHYROIDISM.”

Kasana Rajendra Kumar, Bairwa Ramavatar, Sharma Shrikant and Saxena G. N.

Department of medicine, SMS medical college jaipur, Rajasthan, India.

Manuscript Info

Manuscript History

Received: 15 August 2016

Final Accepted: 19 September 2016

Published: October 2016

Key words:-

Hypothyroidism, overt, levothyroxine, insulin sensitivity, HOMA-IR

Abstract

Objective:- To assess fasting plasma glucose, fasting serum insulin and insulin resistance by oxford HOMA calculator before and after levothyroxine replacement in patients with overt hypothyroidism.

Material and method:- We recruited newly diagnosed overt hypothyroid patients who were prescribed 100 µgm levothyroxine and became euthyroid at 6 week and remained euthyroid at 3 month. These 64 patients were studied for fasting plasma glucose, fasting serum insulin and insulin resistance (HOMA-IR) by oxford HOMA calculator before and at 3 months after levothyroxine treatment.

Results:- Before levothyroxine replacement there was significant ($p < 0.001$) positive correlation between TSH & fasting serum insulin (r value + 0.638), TSH and fasting plasma glucose (r value + 0.506), TSH & HOMA-IR (r value + 0.656) but these correlations were not significant (p value > 0.05) after replacement. Significant decrement was noted (p value < 0.001) in fasting serum insulin (3.73 ± 6.32), fasting plasma glucose (8.06 ± 10.91) and HOMA-IR (0.49 ± 0.78) after levothyroxine replacement.

Conclusion:- In our study overt hypothyroidism was associated with impaired insulin sensitivity which is proportional to thyroid dysfunction and improved with levothyroxine treatment.

Copy Right, IJAR, 2016., All rights reserved.

Introduction:-

The prevalence of hypothyroidism in adult population is approximately 5-10% of woman and 0.5-2% men, the annual incidence rate of autoimmune hypothyroidism is up to 4 per 1000 woman and 1 per 1000 men¹. The prevalence of thyroid disease in patients with diabetes is significantly higher than general population². The term 'thyroid diabetes' was coined in the early literature to depict the influence of thyroid hormone levels on glucose metabolism and for nearly a century, many publications focused on the relationship between diabetes and thyroid disease³.

Evidence for a relationship between T4 and T3 and glucose metabolism appeared over 100 years ago when the influence of thyroid hormone excess in the deterioration of glucose metabolism was first noticed. Since then, it has been known that hyperthyroidism is associated with insulin resistance^{4,5}. More recently, hypothyroidism has also been linked to decreased insulin sensitivity. The explanation to this apparent paradox may lie in the differential

Corresponding Author:- Kasana Rajendra kumar.

Address:- Department of medicine, SMS medical college jaipur, Rajasthan, India.

effects of thyroid hormones at the liver and peripheral tissues level⁶. While thyroid hormones oppose the action of insulin by stimulating hepatic gluconeogenesis and glycogenolysis^{7,8}, on the otherhand it acts synergistically with insulin^{9,10} by up-regulating the expression of genes such as GLUT-4 and phosphoglycerate kinase, involved in glucose transport and glycolysis respectively, in facilitating glucose disposal and utilisation in peripheral tissues.

Compared to the number of reports about insulin resistance in hyperthyroid patients, there are relatively fewer studies in humans dealing with the effects of hypothyroidism on glucose metabolism. Eirini Maratou¹⁵ et al in 2009; Irina kowalska¹² et al in 2011 and Indian study B M Singh¹¹ et al., 2010; demonstrated insulin resistance in hypothyroidism.

Materials and Methods:-

We conducted a hospital based prospective interventional type study in department of medicine, SMS Hospital, Jaipur, Rajasthan. We studied 64 newly diagnosed overt hypothyroid (TSH>5μIU/ml, FT₄<0.89ng/dl and FT₃<1.8pg/ml) patients for insulin sensitivity before and after levothyroxine supplement. Patients included in study were aged between 20-40 yrs, normal hepatic and renal function, not taking any medication known to affect glucose metabolism and became euthyroid after 100 μgm levothyroxine for 6 week and remained euthyroid at 3 months. Excluded were those with age < 20 yrs or > 40 yrs, hepatic and renal dysfunction, seriously ill, polycystic ovarian disease, diabetes mellitus, past history of diabetes mellitus (gestational diabetes mellitus), patient with chronic diseases, pregnancy, menopause and who required levothyroxine dose other than 100 μgm for becoming euthyroid.

On first visit we studied insulin sensitivity by fasting plasma glucose and fasting serum insulin in subjects who were prescribed 100 μgm levothyroxine. After 6 week of 100 μgm levothyroxine, thyroid profile was repeated and those who became euthyroid continued 100 μgm levothyroxine replacement and reviewed at 3 months. After 3 months of 100 μgm levothyroxine replacement those who were euthyroid re-evaluated for insulin sensitivity.

Thyroid profile (TSH, FT₃ and FT₄) and insulin levels were estimated by using electrochemiluminescence immuno assay using commercially available kits. Plasma glucose was measured with glucose oxidase technique on automated autoanalyser. Normal range for TSH was (0.4-4.0) μIU/ml, FT₃ was (1.8-4.2 pg/ml) and that for FT₄ was (0.89-1.76) ng/dl. The normal range for fasting insulin was 6-27 μIU/ml. Data were analyzed by using students paired "T" test, coefficient of correlation and Chi-square test.

Homeostatic model assessment (HOMA):-

HOMA has been widely employed in clinical research to assess insulin sensitivity. Rather than using fasting insulin or a G/I ratio, the product of the fasting values of glucose (expressed as mg/dL) and insulin (expressed as μIU/ml) is divided by a constant. $HOMA-IR = [I.sub.0] \times [G.sub.0]/405$. The constant 405 should be replaced by 22.5 if glucose is expressed in S.I. units. We calculated Insulin resistance by using homeostasis model assessment (HOMA-IR) by Oxford HOMA calculator (<http://www.dtu.ox.ac.uk/homa/index.html>) using the fasting glucose and fasting insulin values. Unlike fasting Insulin and the G/I ratio, the HOMA calculation compensates for fasting hyperglycemia¹³. Also keep in mind that HOMA and fasting insulin values increase in the insulin-resistant patient while the G/I ratio decreases. The HOMA value correlates well with clamp techniques and has been frequently used to assess changes in insulin sensitivity after treatment¹⁴.

Observations and Results:-

In our study females were disproportionately larger in number (78.13%) as compared to males (21.87%) and around 61% of patients were in age group 30 to 39 years (table no.1). There was significant decrease in mean TSH (42.73 ± 15.99 to 2.53 ± 1.21) and significant increase in Mean FT₄ (0.53 ± 0.17 to 1.34 ± 0.25) as well as Mean FT₃ (1.32 ± 0.26 to 3.64 ± 0.97) after levothyroxine replacement (p-value <0.001). Significant decrement in mean fasting insulin 10.37 ± 6.73 to 6.64 ± 3.89 and mean fasting plasma glucose 84.76 ± 9.30 to 76.70 ± 7.23 as well as mean HOMA-IR 1.32 ± 0.83 to 0.83 ± 0.47 after 3 months of levothyroxine replacement (p-value<0.001) as shown in table no.2.

There was significant positive correlation between TSH and Fasting Insulin; TSH and fasting plasma glucose; TSH and HOMA-IR before levothyroxine replacement (r-values +0.638, +0.506 and +0.656 respectively with p-value <0.001) but nonsignificant correlation after levothyroxine replacement (r-values +0.296, +0.162 and +0.285 respectively with p-value >0.05) as shown in table no.3. There was significant negative correlation between T₄ and fasting insulin; T₄ and HOMA-IR before thyroxine replacement (r-value -0.419, -0.427 respectively with p-value

<0.001) but nonsignificant correlation after thyroxine replacement (r-value -0.198, -0.184 respectively with p-value >0.05). There was nonsignificant correlation between T4 and fasting plasma glucose before and after thyroxine replacement (r-value -0.238 and +0.001, p-value >0.05) as shown in table no.4.

Table 1:- Distribution of patients according to age & sex.

Age group (In Yrs)	Sex				Total	
	Male		Female			
	No.	%	No.	%	No.	%
20-29	3	4.69	17	26.56	20	31.25
30-39	10	15.62	29	45.31	39	60.94
40-49	1	1.56	4	6.25	5	7.81
Total	14	21.87	50	78.13	64	100.00

Mean age \pm SD (Male)= 32.35 \pm 4.20

Mean age \pm SD (Female)= 32.32 \pm 5.61

Above table shows that in this study females were disproportionately larger in number (78.13%) as compared to males (21.87%) and around 61% of patients were in age group 30 to 39 years.

Table 2:- change in parameters before and after levothyroxine replacement.

	Mean \pm SD		Mean Change \pm SD	P-value	Significance
	Basal	After 3 month			
TSH	42.73 \pm 15.99	2.53 \pm 1.21	40.20 \pm 15.23	< .001	HS
FT4	0.53 \pm 0.17	1.34 \pm 0.25	0.81 \pm 0.23	< .001	HS
FT3	1.32 \pm 0.26	3.64 \pm 0.97	2.32 \pm 0.98	< .001	HS
F. Insulin	10.37 \pm 6.73	6.64 \pm 3.89	3.73 \pm 6.32	< .001	HS
FPG	84.76 \pm 9.30	76.70 \pm 7.23	8.06 \pm 10.91	< .001	HS
HOMA-IR	1.32 \pm 0.83	0.83 \pm 0.47	0.49 \pm 0.78	< .001	HS

Above table shows that there is significant decrease in TSH but significant increase in FT4, FT3, F. Insulin, FPG, HOMA-IR after levothyroxine replacement

Table 3:- Correlation between TSH and F. Insulin, FPG, HOMA-IR.

Correlation between	Before	P-value	Significance	After	P-value	Significance
	r-value			r-value		
TSH & F.Insulin	+ 0.638	< .001	Sig	+ 0.296	> .05	NS
TSH & FPG	+ 0.506	< .001	Sig	+ 0.162	> .05	NS
TSH & HOMA-IR	+ 0.656	< .001	Sig	+ 0.285	> .05	NS

Correlation between TSH and Fasting Insulin; TSH and fasting plasma glucose; TSH and HOMA-IR is significant and positive before but not significant after levothyroxine replacement

Table 4:- Correlation between T4 and F. Insulin, FPG, HOMA-IR.

Correlation between	r-value	P-value	Significance	After	P-value	Significance
				r-value		
T4 & Insulin	- 0.419	< .001	Sig	- 0.198	> .05	NS
T4 & FPG	- 0.238	> .05	NS	+ 0.001	> .05	NS
T4 & HOMA-IR	- 0.427	< .001	Sig	- 0.184	> .05	NS

There was significant negative correlation between T4 and fasting insulin; T4 and HOMA-IR before but nonsignificant after levothyroxine replacement. On the otherhand T4 and fasting plasma glucose have nonsignificant correlation before and after thyroxine replacement.

Discussion:-

The prevalence of thyroid disease in patients with diabetes is significantly higher than general population². Compared to the number of reports about insulin resistance in hyperthyroid patients, there are relatively fewer studies in humans dealing with the effects of hypothyroidism on glucose metabolism. B.M Singh¹¹ et al in 2010 found that fasting insulin level was significantly higher in hypothyroid (10.56 ± 4.02) compared to controls (5.66 ± 2.9). TSH levels were positively correlated with insulin level (fasting) in patients with hypothyroidism ($r=0.927$, $P<0.01$). They also noticed that mean HOMA-IR was higher in Overt hypothyroidism (3.9 ± 1.32) versus subclinical hypothyroidism (1.7 ± 0.58) as well as in both overt and subclinical as compared to controls (0.57 ± 0.15). TSH levels were positively correlated with HOMA IR in patients with hypothyroidism ($r=0.835$, $P<0.01$). Eirini Maratou¹⁵ et al found that overt hypothyroid and subclinical hypothyroid having higher plasma insulin than the euthyroid ($P<0.05$). They also found that Homeostasis model assessment index was increased in overt hypothyroid (1.97 ± 0.22) and subclinical hypothyroid (1.99 ± 0.13) versus euthyroid (1.27 ± 0.16 , $P<0.05$) suggesting insulin resistance. These results are similar to our study. Irina kowalska¹² et al in 2011 also reported improvement in insulin sensitivity ($p=0.012$) in subclinical hypothyroid patient after levothyroxine replacement by using different technique for measuring insulin sensitivity (hyperinsulinemic euglycemic clamp technique). He also observed a decrease in fasting plasma glucose ($P = 0.019$) after levothyroxine treatment. These results are similar to our study.

Conclusions:-

Our study concluded that overt hypothyroidism is associated with impaired insulin sensitivity which is proportional to thyroid dysfunction. Appropriate treatment of this entity with levothyroxine will not only improve thyroid hormone levels but also improve insulin sensitivity.

Bibliography:-

1. Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 18th ed., Chapter No. 341, New York: McGraw Hill; 2008.
2. Jennal L. Johnson., Daniel S. Duick:- "Diabetes and thyroid disease: A likely combination." Diabetes Spectrum, Volume 15, Number 3, 2002.
3. Seidell JC, Bjorntorp P, Sjostrom L, Sannerstedt R, Krotkiewski M, Kvist H. Regional distribution of muscle and fat mass in men – new insight into the risk of abdominal obesity using computed tomography. *Int J Obes Relat Metab Disord* 1989;13: 289–303.
4. Sathish R. Diabetes and Thyroid Diseases A Review. *Diabetes*. 2003; 23(4):120-3.
5. Bech K, Damsbo P, Eldrup E, Beck-Nielsen H, Roder ME, Hartling SG, et al. β -Cell function and Glucose and lipid oxidation in Graves' disease. *Clinical Endocrinology* 1996;44(1):59-66
6. Brenta, G., Arias, P., Zago et al (2007)- "Lipoprotein alteration, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism: response to l-t(4) treatment". *Thyroid*, 17, 453-460.
7. Weinstein SP, O'Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. *Endocrinology* 1994;135:649–54.
8. Moeller LC, Dumitrescu AM, Walker RL et al. Thyroid hormone responsive genes in cultured human fibroblasts. *J Clin Endocrinol Metab* 2005;90:936–43.
9. Viguerie N, Millet L, Avizou S et al. Regulation of human adipocyte gene expression by thyroid hormone. *J Clin Endocrinol Metab* 2002; 87:630–4.
10. Clement K, Viguerie N, Diehn M et al. In vivo regulation of human skeletal muscle gene expression by thyroid hormone. *Genome Res* 2002;12:281–91.
11. B M Singh. B Goswami and V Mallika Association between Insulin Resistance and Hypothyroidism in Females Attending A Tertiary Care Hospital *Indian Journal of Clinical Biochemistry*, 2010 / 25 (2) 141-145.
12. Irina Kowalska, Jacek Borawski, Agnieszka Nikolajuk, Tadeusz Budlewski, Elzbieta Oziomek, Maria Górska, Marek Strączkowski (MAR 2011) Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy *Endocrine*. Mar 2011.
13. Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. *J Clin Endocrinol Metab*. 2001;85:4615-4617.
14. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. *J Clin Endocrinol Metab*. 2001;86:5457-5464.
15. Maratou E, Hadjidakis DJ, Kollias A et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol* 2009;160:785–90.